Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis.
First-episode psychosis
mega-analysis
multi-centre
neuroanatomy
voxel-based morphometry
Journal
Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
21
12
2019
medline:
27
10
2021
entrez:
21
12
2019
Statut:
ppublish
Résumé
Neuroanatomical abnormalities in first-episode psychosis (FEP) tend to be subtle and widespread. The vast majority of previous studies have used small samples, and therefore may have been underpowered. In addition, most studies have examined participants at a single research site, and therefore the results may be specific to the local sample investigated. Consequently, the findings reported in the existing literature are highly heterogeneous. This study aimed to overcome these issues by testing for neuroanatomical abnormalities in individuals with FEP that are expressed consistently across several independent samples. Structural Magnetic Resonance Imaging data were acquired from a total of 572 FEP and 502 age and gender comparable healthy controls at five sites. Voxel-based morphometry was used to investigate differences in grey matter volume (GMV) between the two groups. Statistical inferences were made at p < 0.05 after family-wise error correction for multiple comparisons. FEP showed a widespread pattern of decreased GMV in fronto-temporal, insular and occipital regions bilaterally; these decreases were not dependent on anti-psychotic medication. The region with the most pronounced decrease - gyrus rectus - was negatively correlated with the severity of positive and negative symptoms. This study identified a consistent pattern of fronto-temporal, insular and occipital abnormalities in five independent FEP samples; furthermore, the extent of these alterations is dependent on the severity of symptoms and duration of illness. This provides evidence for reliable neuroanatomical alternations in FEP, expressed above and beyond site-related differences in anti-psychotic medication, scanning parameters and recruitment criteria.
Sections du résumé
BACKGROUND
Neuroanatomical abnormalities in first-episode psychosis (FEP) tend to be subtle and widespread. The vast majority of previous studies have used small samples, and therefore may have been underpowered. In addition, most studies have examined participants at a single research site, and therefore the results may be specific to the local sample investigated. Consequently, the findings reported in the existing literature are highly heterogeneous. This study aimed to overcome these issues by testing for neuroanatomical abnormalities in individuals with FEP that are expressed consistently across several independent samples.
METHODS
Structural Magnetic Resonance Imaging data were acquired from a total of 572 FEP and 502 age and gender comparable healthy controls at five sites. Voxel-based morphometry was used to investigate differences in grey matter volume (GMV) between the two groups. Statistical inferences were made at p < 0.05 after family-wise error correction for multiple comparisons.
RESULTS
FEP showed a widespread pattern of decreased GMV in fronto-temporal, insular and occipital regions bilaterally; these decreases were not dependent on anti-psychotic medication. The region with the most pronounced decrease - gyrus rectus - was negatively correlated with the severity of positive and negative symptoms.
CONCLUSIONS
This study identified a consistent pattern of fronto-temporal, insular and occipital abnormalities in five independent FEP samples; furthermore, the extent of these alterations is dependent on the severity of symptoms and duration of illness. This provides evidence for reliable neuroanatomical alternations in FEP, expressed above and beyond site-related differences in anti-psychotic medication, scanning parameters and recruitment criteria.
Identifiants
pubmed: 31858920
doi: 10.1017/S0033291719003568
pii: S0033291719003568
pmc: PMC7893510
mid: EMS108535
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
340-350Subventions
Organisme : Wellcome Trust
ID : 208519
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 208519/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_11003
Pays : United Kingdom
Organisme : MRF
ID : MRF_C0439
Pays : United Kingdom
Références
PLoS One. 2012;7(7):e40247
pubmed: 22802957
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Schizophr Res. 2000 Nov 30;46(1):35-43
pubmed: 11099884
Neuroimage. 2003 Jun;19(2 Pt 1):365-75
pubmed: 12814586
Psychiatry Res. 2015 Feb 28;231(2):176-83
pubmed: 25595222
Psychopharmacol Bull. 2003 Spring;37(2):79-101
pubmed: 14566217
Psychol Med. 2017 Jul;47(9):1637-1646
pubmed: 28183367
PLoS One. 2017 May 17;12(5):e0177251
pubmed: 28520743
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Schizophr Res. 2014 Oct;159(1):62-9
pubmed: 25178803
Biol Psychiatry. 2011 Jul 1;70(1):88-96
pubmed: 21457946
Int J Methods Psychiatr Res. 2012 Sep;21(3):205-21
pubmed: 22419500
Prog Neuropsychopharmacol Biol Psychiatry. 2005 May;29(4):587-91
pubmed: 15866362
Neuroimage. 2009 Jan 15;44(2):319-27
pubmed: 18929669
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
Schizophr Res. 2010 Nov;123(2-3):93-104
pubmed: 20832997
Schizophr Res. 2005 Mar 1;73(2-3):235-41
pubmed: 15653266
Psychol Med. 2017 Feb;47(3):401-413
pubmed: 27776571
Nat Rev Neurosci. 2009 Dec;10(12):885-92
pubmed: 19904278
Schizophr Bull. 2015 Nov;41(6):1266-75
pubmed: 26264820
Sci Rep. 2015 Sep 25;5:14505
pubmed: 26403064
Am J Psychiatry. 2004 Feb;161(2):322-31
pubmed: 14754782
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Nat Rev Neurosci. 2013 May;14(5):365-76
pubmed: 23571845
Schizophr Bull. 2014 Mar;40 Suppl 2:S107-16
pubmed: 24375459
Biol Psychiatry. 2008 Jul 1;64(1):40-7
pubmed: 18549875
Arch Gen Psychiatry. 1992 Aug;49(8):615-23
pubmed: 1637251
Neurosci Lett. 2011 Feb 4;489(2):110-4
pubmed: 21138755
Schizophr Bull. 2018 Aug 20;44(5):1035-1044
pubmed: 29186619
Schizophr Res. 2008 Sep;104(1-3):44-60
pubmed: 18703313
Schizophr Bull. 2015 Jan;41(1):192-200
pubmed: 24361862
Neurosci Biobehav Rev. 2010 Jul;34(8):1207-22
pubmed: 20144653
Schizophr Res. 2012 Dec;142(1-3):248-9
pubmed: 23043873
Indian J Psychiatry. 2010 Jan;52(1):28-36
pubmed: 20174515
Trends Cogn Sci. 2000 Jun;4(6):223-233
pubmed: 10827445
Schizophr Res. 2014 Jan;152(1):289-94
pubmed: 24332632
Am J Psychiatry. 2013 Nov;170(11):1308-16
pubmed: 23732942
Schizophr Bull. 2011 Jul;37(4):690-9
pubmed: 21700589
Biol Psychiatry. 2008 Nov 1;64(9):774-81
pubmed: 18486104
Cortex. 2013 Apr;49(4):1046-55
pubmed: 22370252
Psychiatry Res. 2018 Apr;262:494-499
pubmed: 28967441
Transl Psychiatry. 2012 Nov 20;2:e190
pubmed: 23168990
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):84-90
pubmed: 20832444
Early Interv Psychiatry. 2008 Aug;2(3):178-87
pubmed: 21352151
Psychiatry Res. 2015 Mar 30;231(3):298-307
pubmed: 25659473
Schizophr Res. 2010 Mar;117(1):1-12
pubmed: 20071149
Eur Neuropsychopharmacol. 2018 Mar;28(3):392-400
pubmed: 29338891
Schizophr Bull. 2015 Sep;41(5):1133-42
pubmed: 25548384
Schizophr Res. 2015 May;164(1-3):74-82
pubmed: 25687531
Schizophr Res. 2011 Nov;132(2-3):131-4
pubmed: 21795025
J Psychiatry Neurosci. 2018 Mar;43(2):131-142
pubmed: 29481320
Schizophr Res. 2007 Jan;89(1-3):12-21
pubmed: 17098398
Schizophr Res. 2003 Apr 1;60(2-3):173-81
pubmed: 12591581
Nat Rev Neurosci. 2005 Sep;6(9):691-702
pubmed: 16136173
Br J Psychiatry. 1988 Oct;153:437-43
pubmed: 3074851
Schizophr Bull. 2012 Nov;38(6):1297-307
pubmed: 22080494
PLoS One. 2011;6(6):e21047
pubmed: 21712987
Neurology. 2000 Feb 22;54(4):849-54
pubmed: 10690975
Schizophr Bull. 2008 Sep;34(5):848-55
pubmed: 18628272
Schizophr Res. 2013 May;146(1-3):308-13
pubmed: 23522907
Neurosci Biobehav Rev. 2012 Nov;36(10):2325-33
pubmed: 22910680
Neuroimage. 2006 Aug 15;32(2):842-53
pubmed: 16757180
Biol Psychiatry. 2012 Mar 15;71(6):552-60
pubmed: 22281121
J Neuropathol Exp Neurol. 2000 Feb;59(2):137-50
pubmed: 10749103
J Psychiatry Neurosci. 2009 Nov;34(6):418-32
pubmed: 19949718
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Biol Psychiatry. 2005 Jul 15;58(2):151-7
pubmed: 15922309
Biol Psychiatry. 2000 Jul 15;48(2):110-9
pubmed: 10903407
Brain. 2008 Jan;131(Pt 1):180-95
pubmed: 18056163
Psychol Med. 2016 Jul;46(10):2201-14
pubmed: 27228263
Brain Struct Funct. 2010 Jun;214(5-6):655-67
pubmed: 20512370
Front Psychiatry. 2014 Jan 08;4:182
pubmed: 24409157
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
Psychiatry Res. 2006 Jun 30;147(1):47-55
pubmed: 16545554
Hum Brain Mapp. 2007 Nov;28(11):1213-22
pubmed: 17266108
Neuropsychopharmacology. 2019 Apr;44(5):869-875
pubmed: 30127342
Biol Psychiatry. 2018 Nov 1;84(9):644-654
pubmed: 29960671
Sex Health. 2017 Oct;14(5):423-430
pubmed: 29216968
Schizophr Res. 2011 Apr;127(1-3):46-57
pubmed: 21300524
Hum Brain Mapp. 2009 Aug;30(8):2530-41
pubmed: 19072895
Schizophr Bull. 2011 Jan;37(1):177-88
pubmed: 19633214
Am J Psychiatry. 2008 Aug;165(8):1015-23
pubmed: 18381902
Biol Psychiatry. 2015 Sep 15;78(6):403-12
pubmed: 25802081
J Psychiatr Res. 2015 Jun;65:80-6
pubmed: 25937503
Biol Psychiatry. 2002 Jan 1;51(1):59-67
pubmed: 11801231
Nat Rev Neurosci. 2015 Oct;16(10):620-31
pubmed: 26373471